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PERSPECTIVE
Model- Informed Precision Dosing at the Bedside: 
Scientific Challenges and Opportunities
Ron J. Keizer1,*, Rob ter Heine2, Adam Frymoyer3, Lawrence J. Lesko4, Ranvir Mangat1 and Srijib Goswami1
The development of model- informed precision dosing (MIPD) tools, especially in the form of native or web- based applications 
to be used at the bedside, has garnered marked attention in recent years. Their potential clinical benefit can be large, but it 
should be ensured that such tools make optimal use of available clinical data and have adequate predictive ability. Unique 
scientific challenges specific to MIPD remain, which may require adaptation of commonly used diagnostics in 
pharmacometrics.
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In 1969, Lewis B. Sheiner1 published a paper that can now 
only be described as seminal, as it launched the field of 
pharmacometrics as we know it. This paper, and similar 
work done in the early 1970s by Roger Jelliffe and his group 
at USC, demonstrated the rudimentary concepts of how 
clinical pharmacokinetic (PK) data can be fed into computer- 
based algorithms to optimize drug treatment for patients. In 
the ensuing 5 decades, the field of pharmacometrics has 
grown markedly. Although model- informed precision dosing 
(MIPD), a recently introduced label, has always attracted a 
subset of clinical researchers, it seems to have gained re-
newed attention from the modeling community, evidenced 
by the release of new software tools, the publication of opin-
ion papers,2–4 the scheduling of various dedicated confer-
ence sessions (ASCPT, PAGE, ACoP, and ACCP), and the 
creation of a Special Interest Group within ISoP (“Applied 
Clinical Pharmacometrics”).
MIPD generally requires custom- made software tools 
because generic modeling software, such as MATLAB or 
NONMEM, is too cumbersome and complex for most prac-
ticing clinical providers to learn and apply. Dedicated tools 
are likely to come in the form of a mobile or web- based 
application that contains algorithms for drawing inference 
from available clinical data and evaluating future personal-
ized treatment courses. For any academic or commercial 
MIPD tool to be applied successfully at the point- of- care, 
a considerable number of technical, organizational, regula-
tory, and financial hurdles need to be overcome, some of 
which have been highlighted before.2 Furthermore, to drive 
adoption of these tools in the clinic practice, it is essential 
to provide proper education of the intended end- user, and 
provide proof of improved efficacy, reduced toxicity, and/or 
reduced costs, preferably from prospective clinical trials.5 
Finally, even though the science of pharmacometrics has 
progressed considerably, within the subfield of MIPD, a con-
siderable number of scientific challenges still remain.
MODEL SELECTION
An obvious first question that should be answered for any 
MIPD tool concerns the selection of the underlying model 
or models. Intuitively, one needs to select a model that 
matches the intended population. In practice, this usually 
means matching age groups (neonate, pediatric, adult, 
and geriatric), body composition (normal, cachectic, and 
obese), indications and comorbidities, and potentially ge-
netic makeup (e.g., cytochrome P450 genotype), as well as 
dose levels studied and analytical assay(s) used.6 For some 
drugs, models have been developed that scale over a wide 
age range, but most often models are developed over lim-
ited ranges, making it potentially hazardous to extrapolate 
or generalize. Similarly, many clinical datasets only contain 
limited numbers of a certain subgroup (e.g., obese pa-
tients), thereby making it challenging to capture the specific 
impact of the characteristics for that subgroup.
Even once we have identified an appropriate model to 
use in a specific patient population, and we have made sure 
its numerical performance is the same (or highly similar) to 
the platform on which it was developed, we are still not in 
the clear. Naively implementing such a model into point- of- 
care software would assume that the population on which 
the model was built will be exactly the same as the intended 
population (e.g., when drawing inference based on maxi-
mum a priori estimates), one will be making the bold as-
sumption that the model is unbiased and that population 
parameters follow distributions with the same magnitude as 
observed in the studied population (which is usually from 
a different hospital, often from a different country). These 
assumptions often do not hold and limit the scalability of a 
given model across institutions. We have seen several cases 
in which published models did not perform well for individ-
ual patients, an observation reported before, for example, 
by Neef et al.7 Therefore, we recommend evaluation of the 
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predictive ability of the intended model for its intended use 
before applying it in the clinic, and to continuously monitor 
it once deployed. Specialized analytic dashboards could be 
implemented to inform clinical providers and hospital man-
agement on the population- level performance of the imple-
mented MIPD tool, for example, in terms of favorable clinical 
outcomes or, for antibiotics, target attainment rates.
MODEL QUALIFICATION
Evaluation of model performance in the same clinical set-
ting and scenario of application is critical. Such a qualifi-
cation step can be done using historical data drawn from 
the clinical records of the institution in which the tool is 
meant to be implemented. For example, when implement-
ing a decision tool to determine the optimal starting dose, 
the a priori predictive value is important: ensuring that the 
model has good predictive value using only the information 
that will be available for patients at the time of starting dose 
selection. When the intention is to use the model in the set-
ting of biomarker- based dosing, such as therapeutic drug 
monitoring, the a posteriori predictive performance is more 
important: the predictive ability after biomarker data has 
been used to inform the model parameters, which can, for 
example, be obtained by forecasting future exposure from 
repeated subsetting and fitting of subjects’ historical data. 
Many diagnostic tools that have been developed for model 
development can also be used in this context, but often do 
not directly answer whether the model is fit for purpose. 
New dedicated tools will be necessary to allow easy and 
standardized evaluation of the predictive or prognostic abil-
ity of models within their intended clinical application.
MITIGATING MODEL BIAS AND IMPROVING 
PREDICTIVE VALUE
Even when a model has been selected and has shown ac-
ceptable performance in a fit for purpose qualification proce-
dure, it is likely that when used in clinical practice the model 
will be challenged by patients with more “extreme” PK/ 
pharmacodynamic characteristics than expected (i.e., “out-
liers” that deserve special attention). To some extent, this 
is expected due to the fact that, for example, (i) the model 
is only a product of the limited number of patients it was 
built on, (ii) the distribution of model parameters might be 
misspecified or its magnitude overestimated or underesti-
mated, (iii) the magnitude of process noise (e.g., errors in 
sample or dose timing) is often higher in clinical practice 
than in a trial setting, (iv) the model has inherent bias (e.g., 
from missing data), but was deemed acceptable in qualifica-
tion, and/or (v) selection bias (e.g., from selectively applying 
biomarker dosing tools to patients), which show toxicity or 
poor response.
One way to mitigate poor fit and potentially poor predic-
tive ability for extreme patients is to flatten or downweigh 
the model priors in the likelihood function. This will allow 
for more extreme individual parameter estimates to be es-
timated for the patient, thus, to rely more on the observed 
data, and potentially improve predictive ability. If possible, 
gathering more data on the patient should of course be a 
priority in such a case to confirm or disprove the outlying in-
dividual parameter estimates. Although somewhat arbitrary, 
this approach does provide more flexibility in using existing 
models for patients that are showing more extreme behavior 
or are outside the scope of the original study’s population. 
We do need to keep in mind that a better fit does not neces-
sarily result in better predictive ability, so some degree of re-
liance on prior estimates is required to avoid overfitting, and 
this approach should be explored during qualification before 
it can be recommended generically. A similar approach of 
prior modification to optimize fit and predictive ability has 
been advocated in the nonparametric setting, in which the 
grid of support points has been proposed to be extended 
with a second grid around the maximum a priori Bayesian 
estimates.8
Additionally, although a chosen model might in some 
cases show suboptimal predictive performance when first 
applied in clinical practice, data collected in the tool could 
subsequently be used to update the model structure or 
model parameters to match the intended clinical popula-
tion better (i.e., a “learning model”). Over time, the need for 
strategies to improve fit and predictive ability, as discussed 
above, should then be reduced. If implemented in a (semi- )
automated manner, this will result in a cycle where the model 
is updated continuously, as shown in Figure 1. Clinical 
data is often messy and incomplete, so curation and data 
cleaning should be key considerations in such a workflow, 
whereas one should also be careful that the use of routinely 
collected data does not introduce bias in the model.9
CHANGES OVER TIME
A third challenge concerns the handling of the interoccasion 
variability (IOV) arising from the time- varying nature of indi-
vidual patient physiology and PK and pharmacodynamics. A 
first aspect is the interpretation of covariates and individual 
parameter estimates from previous visits: do these histor-
ical data points have predictive value for future treatment 
courses? Should data with potential predictive value from 
Figure 1 Proposed workflow for model- informed precision 
dosing (MIPD) tools at the bedside.
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more recent visits be given more weight? In pediatrics, in 
which physiology is changing more rapidly than in adults, 
should we allow a shorter time span of historical data to in-
form future treatment? We and several other groups (e.g., 
Abrantes et al.,10 Wicha et al.11) are investigating such ques-
tions, but little work on this topic has been done to date.12 
Incorporation of IOV is important for characterization of both 
short- term (e.g., within- day, for the same visit or treatment 
course) and long- term (between- visit) treatment scope. If 
IOV is not properly accounted for, downweighing or ignoring 
historical data might be needed to avoid bias in individual 
parameter estimates, which, again, should ideally be evalu-
ated during model qualification.
CONCLUSION
We have highlighted several practical scientific challenges 
commonly encountered when developing and implementing 
MIPD tools at the point- of- care. “Fit for purpose” qualifica-
tion is a key step when developing and implementing MIPD 
tools for use at the bedside, in which conventional model 
diagnostics are often only of limited value. Further method-
ological research into this area is needed, especially around 
diagnostics for model qualification and the weighing and 
proper interpretation of historical data and model priors.
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